on PREDILIFE (EPA:ALPRE)
Predilife: Solid 2025 half-year results despite uncertainties
Predilife, a company specializing in disease risk prediction solutions, announced a 148% increase in its revenue in the first half of 2025, reaching €392,773 compared to €157,900 in 2024. Deferred revenue increased fivefold, reflecting contracts in progress. This performance is explained by the growing demand from companies for predictive health assessments. However, Predilife is operating in a fragile financial environment, with uncertainties regarding its short-term cash flow. The company plans to increase its capital to secure its financing and continue its development.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PREDILIFE news